Serum Sestrin2 Was Lower in Septic Shock Patients with Cardiomyopathy

Abstract

Background. To determine the clinical significance of variations in serum sestrin2 protein levels in the development of septic cardiomyopathy in septic shock patients. Methods. The serum sestrin2 concentrations of each sample were determined using ELISA in a total of 67 control persons and 188 patients with septic shock. Furthermore, using transthoracic echocardiography, septic shock patients were split into two groups based on whether or not cardiomyopathy had developed, and the differences in each index between the two groups were analyzed. We looked at the relationship between serum sestrin2 levels, norepinephrine dosage, and NTproBNP levels. The influencing variables for the prediction of septic cardiomyopathy linked with the development of septic cardiomyopathy and clinical prognosis in septic cardiomyopathy were determined using multivariate binary logistic regression. Results. Assessment of left ventricular systolic function by measurement of LVEF revealed that 61/188 (32.4%) of the 188 patients with septic shock included in the research satisfied the diagnostic criteria for septic cardiomyopathy. (1) Sestrin2 protein levels showed a significant difference between septic shock and healthy controls ( p < 0.01 ). (2) Compared to the group without septic cardiomyopathy, the group with combined septic cardiomyopathy had lower serum sestrin2 protein levels ( p < 0.05 ), lower systolic blood pressure ( p < 0.05 ), and higher plasma NTproBNP levels ( p < 0.01 ) and used greater norepinephrine dosages ( p < 0.01 ). The levels of serum sestrin2 protein revealed a little negative relationship with NTproBNP and norepinephrine dose. However, a binary logistic regression analysis revealed that none of these factors was an independent predictor of septic shock. (3) Age, lactate level, SOFA score, positive bacteremia, and sestrin2 protein were shown to be substantial discrepancies in clinical outcomes in patients with septic cardiomyopathy, becoming variables that impact clinical outcomes. Positive bacteremia ( p = 0.031 , OR = 5.084), SOFA score ( p = 0.021 , OR = 1.304), and sestrin2 protein ( p = 0.039 , OR = 0.897) were revealed to have independent influences in predicting clinical mortality outcome in septic cardiomyopathy using multivariate binary logistic regression. Conclusion. High serum sestrin2 levels clearly distinguish septic shock patients from healthy controls, whereas low serum sestrin2 levels are related with cardiac dysfunction to some extent but are not an independent influence factor for septic cardiomyopathy. Low serum sestrin2 levels were shown to be useful in predicting clinical outcome in patients with septic cardiomyopathy.

Sestrin2 as a Protective Shield against Cardiovascular Disease

“…Consistent results were obtained in vivo in a mouse model where SESN2 deletion increased the expression of cardiac fibrotic factors, collagen I and III, in addition to MMP2 and MMP9. High serum levels of SESN2 clearly could distinguish septic shock patients from healthy controls, whereas low circulating levels of SESN2 are related to cardiac dysfunction to some extent but are not an independent influence factor for septic cardiomyopathy [87]. Low circulating levels of SESN2 were shown to be useful in predicting clinical outcomes in patients with septic cardiomyopathy [88].…”

Sestrin2 in diabetes and diabetic complications

“…Sestrin2 suppression aggravates ER stress-induced oxidative stress and apoptosis in endothelial cells ( 182 ). Clinically, several studies have investigated the variations in plasma Sestrin2 protein levels in patients with cardiomyopathy and/or heart failure, and displayed conflicting results ( 183 – 185 ). Wang et al.…”

“…Also, plasma Sestrin2 levels were found to be increased in patients with coronary heart disease (CAD) and positively related to the severity of CAD ( 184 , 186 ). However, lower serum Setrin2 levels were indicated in patients with septic cardiomyopathy and in T2DM patients with CHD ( 126 , 185 ). Low Sestrin2 level was a risk factor for CHD in T2DM patients ( 126 ).…”

“…Sestrin2 suppression aggravates ER stressinduced oxidative stress and apoptosis in endothelial cells (182). Clinically, several studies have investigated the variations in plasma Sestrin2 protein levels in patients with cardiomyopathy and/or heart failure, and displayed conflicting results (183)(184)(185). Wang et al reported that plasma Sestrin2 level was increased in patients with chronic heart failure (CHD) and was positively related to the severity of CHD.…”